Arimidex (anastrozole) is now approved as first-line therapy of advanced breast cancer

July 2000

Arimidex (anastrozole) is now approved as first-line therapy of advanced breast cancer in Canada. It's still second-line in the U.S.

It's an alternative to tamoxifen for postmenopausal women with estrogen receptor-positive breast cancer.

Until now, Arimidex was approved only as second-line therapy...when breast cancer progressed despite treatment with tamoxifen.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote